Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 15  CAOLD to be discontinued on December 31, 2008
 NEWS  3  OCT 07  EPFULL enhanced with full implementation of EPC2000
 NEWS  4  OCT 07  Multiple databases enhanced for more flexible patent
                  number searching
 NEWS  5  OCT 22  Current-awareness alert (SDI) setup and editing
                  enhanced
 NEWS  6  OCT 22  WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                  Applications
 NEWS  7  OCT 24  CHEMLIST enhanced with intermediate list of
                  pre-registered REACH substances
 NEWS  8  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  9  NOV 26  MARPAT enhanced with FSORT command
 NEWS 10  NOV 26  MEDLINE year-end processing temporarily halts
                  availability of new fully-indexed citations
 NEWS 11  NOV 26  CHEMSAFE now available on STN Easy
 NEWS 12  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS 13  DEC 01  ChemPort single article sales feature unavailable
 NEWS 14  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:48:15 ON 15 DEC 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:48:42 ON 15 DEC 2008

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 DEC 2008 HIGHEST RN 1083471-57-1
DICTIONARY FILE UPDATES: 12 DEC 2008 HIGHEST RN 1083471-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading c:\program files\stnexp\queries\10537495a.str

L1   STRUCTURE UPLOADED

=>
Uploading c:\program files\stnexp\queries\10537495.str

L2   STRUCTURE UPLOADED

=> s l1 full
FULL SEARCH INITIATED 15:50:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   55 TO ITERATE

100.0% PROCESSED   55 ITERATIONS   2 ANSWERS
SEARCH TIME: 00.00.01

L3   2 SEA SSS FUL L1

=> s l2 full
FULL SEARCH INITIATED 15:50:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1 TO ITERATE

100.0% PROCESSED   1 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

L4   1 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                      ENTRY   SESSION
FULL ESTIMATED COST   357.18   357.39

FILE 'CAPLUS' ENTERED AT 15:50:36 ON 15 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Dec 2008 VOL 149 ISS 25
FILE LAST UPDATED: 14 Dec 2008 (20081214/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l3
L5           1 L3

=> s l4
L6           1 L4

=> s l5 or l6
L7           2 L5 OR L6

=> d bib abs hitstr 1-2 l7

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2004:568609  CAPLUS
DN   141:117169
TI   Human SGLT1 inhibitors containing benzylphenyl glucopyranoside or
     galactopyranoside derivatives
IN   Yonekubo, Shigeru; Shimizu, Kazuo; Shibazaki, Toshihide; Tomae, Masaki;
     Isaji, Masayuki
PA   Kissei Pharmaceutical Co., Ltd., Japan
SO   Jpn. Kokai Tokkyo Koho, 90 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    --------------------   --------
PI   JP 2004196788        A     20040715    JP 2003-404247         20031203
PRAI JP 2002-352251       A     20021204
OS   MARPAT 141:117169
GI
```



I

```
AB   The invention provides human glucose-sodium cotransporter (SGLT1)
     inhibitors containing benzylphenol derivative represented by the following general
     formula I [R1 = OH, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, hydroxy(C1-6
     alkyl), etc.; R2 = H, C1-6 alkyl, C1-6 alkoxy, phenoxy, phenylthio,
     phenylamino, halogen; R3, R4, R5 = H, C1-6 alkyl, C1-6 alkoxy, halogen; R6
     = H, C1-6 alkyl; R7 = H, OH, amino, mono/di(C1-6 alkyl)amino, C1-6 alkyl,
     C1-6 alkoxy, hydroxy(C1-6 alkyl), carbamoyl(C1-6 alkyl); G =
     β-D-glucopyranosyl, β-D-galactopyranosyl] and pharmacol.
     acceptable salts or prodrugs thereof.  A compound
     5-hydroxy-3-methyl-2-[4-[(E)-2-[2-
     (sulfamoylamino)ethylcarbamoyl]vinyl]benzyl]phenyl
     β-D-glucopyranoside was prepared, and tested for its effect on human
     SGLT1 activity in vitro, and on blood glucose level in rats.
IT   721969-17-1P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (human SGLT1 inhibitors containing benzylphenyl glucopyranoside or
        galactopyranoside derivs.)
RN   721969-17-1  CAPLUS
CN   Urea, N-[4-[[2-(β-D-glucopyranosyloxy)-4-hydroxy-6-
     methylphenyl]methyl]phenyl]-N'-(2-pyridinylmethyl)-  (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:182896 CAPLUS
DN 140:236000
TI Preparation of 4-benzylpyrazolyl glucopyranosides and galactopyranoside derivatives as sodium-glucose cotransporter (SGLT1) inhibitors, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
IN Fushimi, Nobuhiko; Shimizu, Kazuo; Yonekubo, Shigeru; Teranishi, Hirotaka; Tomae, Masaki; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018491	A1	20040304	WO 2003-JP10551	20030821
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004137245	A	20040513	JP 2002-324076	20021107
	CA 2496329	A1	20040304	CA 2003-2496329	20030821
	AU 2003262263	A1	20040311	AU 2003-262263	20030821
	EP 1548024	A1	20050629	EP 2003-792760	20030821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013694	A	20050705	BR 2003-13694	20030821
	CN 1688597	A	20051026	CN 2003-824499	20030821
	ZA 2005001549	A	20060726	ZA 2005-1549	20030821
	NZ 538423	A	20070223	NZ 2003-538423	20030821
	US 20050272669	A1	20051208	US 2005-525197	20050222
	MX 2005PA02129	A	20050603	MX 2005-PA2129	20050223
	NO 2005001411	A	20050426	NO 2005-1411	20050317
	IN 2007DN07100	A	20071012	IN 2007-DN7100	20070913
PRAI	JP 2002-244381	A	20020823		
	JP 2002-324076	A	20021107		
	WO 2003-JP10551	W	20030821		
	IN 2005-DN666	A3	20050221		

OS MARPAT 140:236000
GI



I

AB Pyrazole derivs. represented by the general formula (I) [R1 = H, C1-6 alkyl, C2-6 alkenyl, hydroxy-C2-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, each (un)substituted aryl or aryl-C1-6 alkyl; one of Q and T = Q1 or Q2 and the other = C1-6 alkyl, halo-C1-5 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-7 cycloalkyl; R2 = H,halo, OH, C1-6 alkyl, C1-6 alkoxy,C1-6 alkylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C3-7 cycloalkyl-C2-6 alkoxy, etc.; X = a single bond, O, S; Y = optionally hydroxy-substituted C1-6 alkylene or C2-6 alkenylene; Z = RB, CORC, SO2RC, CO(RD)RE, SO2NHRF, C(:NRG)N(RH)RI; wherein RC = each (un)substituted aryl, heteroaryl, or C1-6 alkyl; R4, RB, RD, RE, RF = H, each (un)substituted aryl, heteroaryl, or C1-6 alkyl; NR4RB or NRDRE together forms (un)substituted C2-6 cyclic amino; RG, RH, RI = H, (un)substituted C1-6 alkyl, etc.; R3, R5, R6 = H, halo, C1-6 alkyl, C1-6 alkoxy] or pharmacol. acceptable salts thereof are prepared These compds. have excellent human SGLT1 inhibitory activity and are useful as preventives or therapeutic agents for diseases attributable to hyperglycemia such as diabetes, impaired glucose tolerance, fasting blood sugar abnormality, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hypertriglyceridemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, and gout and for diseases attributable to an increased blood galactose level such as galactosemia. For example, 3-(β-D-glucopyranosyloxy)-4-[[4-[3-[3-(2-hydroxy-1,1-dimethylethyl)ureido]propoxy]-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole in vitro inhibited the uptake of [14C]methyl α-D-glucopyranoside in CHO-K1 cells expressing human SGLT1 with IC50 of 19 nM. For another example, 3-(β-D-glucopyranosyloxy)-4-[[4-(2-guanidinoethoxy)-2-methylphenyl]methyl]-5-isopropyl-1H-pyrazole at 1 mg/kg p.o. lowered the serum glucose concentration from 303±63 (control) to 165±17 mg/dL after 1 h in rats with streptozotocin-induced diabetes.

IT 666842-40-6P 666842-61-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylpyrazolyl glucopyranosides and galactopyranosides as sodium-glucose cotransporter (SGLT1) inhibitors for prevention or treatment of diseases attributable to hyperglycemia or galactosemia)

RN 666842-40-6 CAPLUS

CN Guanidine, [2-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 666842-61-1 CAPLUS
CN Methanesulfonamide, N-[[[2-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]ethyl]amino][(2-hydroxyethyl)amino]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT